Chronic administration of risperidone in a rat model of schizophrenia: A behavioural, morphological and molecular study

Página do item simplificado
dc.contributor.authorCastellano, O.
dc.contributor.authorArji, M.
dc.contributor.authorSancho, C.
dc.contributor.authorCarro, J.
dc.contributor.authorRiolobos, A. S.
dc.contributor.authorMolina, V.
dc.contributor.authorGómez-Nieto, R.
dc.contributor.authorde Anchieta de Castro e Horta, José [UNESP]
dc.contributor.authorHerrero-Turrión, M. J.
dc.contributor.authorLópez, D. E.
dc.contributor.institutionInstitute for Neuroscience of Castilla y León
dc.contributor.institutionUniversity of Salamanca
dc.contributor.institutionUniversity of Valladolid
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:28:44Z
dc.date.available2014-05-27T11:28:44Z
dc.date.issued2013-04-01
dc.description.abstractIn the present work we analyzed the effect of the chronic administration of risperidone (2mg/kg over 65 days) on behavioural, morphological and molecular aspects in an experimental model of schizophrenia obtained by bilateral injection of ibotenic acid into the ventral hippocampus of new-born rats. Our results show that during their adult lives the animals with hippocampal lesions exhibit different alterations, mainly at behavioural level and in the gene expression of dopamine D2 and 5-HT2A receptors. However, at morphological level the study performed on the prefrontal cortex did not reveal any alterations in either the thickness or the number of cells immunoreactive for c-Fos, GFAP, CBP or PV. Overall, risperidone administration elicited a trend towards the recovery of the values previously altered by the hippocampal lesion, approaching the values seen in the animals without lesions. It may be concluded that the administration of risperidone in the schizophrenia model employed helps to improve the altered functions, with no significant negative effects. © 2013.en
dc.description.affiliationInstitute for Neuroscience of Castilla y León, Salamanca
dc.description.affiliationDepartment of Cell Biology and Pathology University of Salamanca, Salamanca
dc.description.affiliationDepartment of Physiology and Pharmacology University of Salamanca, Salamanca
dc.description.affiliationDepartment of Basic Psychology, Psychobiology and Methodology University of Salamanca, Salamanca
dc.description.affiliationDepartment of Psychiatry School of Medicine University of Valladolid
dc.description.affiliationInstitute of Biomedical Research of Salamanca (IBSAL) University of Salamanca, Salamanca
dc.description.affiliationBiosciences Institute São Paulo State University (UNESP), Campus of Botucatu
dc.description.affiliationUnespBiosciences Institute São Paulo State University (UNESP), Campus of Botucatu
dc.format.extent178-190
dc.identifierhttp://dx.doi.org/10.1016/j.bbr.2012.12.036
dc.identifier.citationBehavioural Brain Research, v. 242, n. 1, p. 178-190, 2013.
dc.identifier.doi10.1016/j.bbr.2012.12.036
dc.identifier.issn0166-4328
dc.identifier.issn1872-7549
dc.identifier.scopus2-s2.0-84872578236
dc.identifier.urihttp://hdl.handle.net/11449/74912
dc.identifier.wosWOS:000315660100022
dc.language.isoeng
dc.relation.ispartofBehavioural Brain Research
dc.relation.ispartofjcr3.173
dc.relation.ispartofsjr1,413
dc.rights.accessRightsAcesso restrito
dc.sourceScopus
dc.subject5-HT receptor
dc.subjectAntipsychotic drugs
dc.subjectBehaviour
dc.subjectDA receptor
dc.subjectImmunohistochemistry
dc.subjectPrefrontal cortex
dc.subjectRisperidone
dc.subjectSchizophrenia
dc.subjectcalbindin
dc.subjectdopamine 2 receptor
dc.subjectglial fibrillary acidic protein
dc.subjectibotenic acid
dc.subjectparvalbumin
dc.subjectprotein c fos
dc.subjectrisperidone
dc.subjectserotonin 2A receptor
dc.subjectadult animal
dc.subjectanimal behavior
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectanimal tissue
dc.subjectbrain damage
dc.subjectcell count
dc.subjectchronic drug administration
dc.subjectcontrolled study
dc.subjectcortical thickness (brain)
dc.subjectdisease model
dc.subjectgene expression
dc.subjecthippocampus
dc.subjectimmunoreactivity
dc.subjectnewborn
dc.subjectnonhuman
dc.subjectnucleotide sequence
dc.subjectprefrontal cortex
dc.subjectpriority journal
dc.subjectrat
dc.subjectschizophrenia
dc.subjectAge Factors
dc.subjectAnimals
dc.subjectAnimals, Newborn
dc.subjectAntipsychotic Agents
dc.subjectAvoidance Learning
dc.subjectBehavior, Animal
dc.subjectBrain
dc.subjectCell Count
dc.subjectCREB-Binding Protein
dc.subjectDisease Models, Animal
dc.subjectDrug Administration Schedule
dc.subjectExcitatory Amino Acid Agonists
dc.subjectExploratory Behavior
dc.subjectFemale
dc.subjectGene Expression Regulation
dc.subjectGlial Fibrillary Acidic Protein
dc.subjectGrooming
dc.subjectHippocampus
dc.subjectIbotenic Acid
dc.subjectMale
dc.subjectParvalbumins
dc.subjectProto-Oncogene Proteins c-fos
dc.subjectRats
dc.subjectRats, Wistar
dc.subjectReceptor, Serotonin, 5-HT2A
dc.subjectReceptors, Dopamine D2
dc.titleChronic administration of risperidone in a rat model of schizophrenia: A behavioural, morphological and molecular studyen
dc.typeArtigo
dcterms.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
unesp.author.orcid0000-0003-2457-2487[6]
unesp.author.orcid0000-0003-3639-9861[8]
unesp.author.orcid0000-0002-7556-9782[4]
unesp.author.orcid0000-0002-8972-6822[7]
unesp.author.orcid0000-0002-1450-7246[10]
unesp.author.orcid0000-0002-6692-878X[1]

Arquivos

Coleções

Artigos